Saroglitazar Beyond Triglycerides


Dr RK Marya, New Delhi    01 February 2018

Saroglitazar is a dual PPAR agonist, currently approved in India for the treatment of diabetic dyslipidemia (hypertriglyceridemia in type 2 diabetes). It improves insulin sensitivity and lipid abnormalities (TG and non-HDL-C). It improves glycemic control. Preclinical trials - improves multiple markers of insulin resistance and NAFLD/NASH. Post-marketing clinical data - improvement in liver enzymes, liver fat content and glycemic parameters. It lowers TGs and addresses abnormal fat distribution in HIV lipodystrophy.

To comment on this article,
create a free account.

Sign Up to instantly get access to 10000+ Articles & 1000+ Cases

Already registered?

Login Now

Most Popular Articles

News and Updates

eMediNexus provides latest updates on medical news, medical case studies from India. In-depth medical case studies and research designed for doctors and healthcare professionals.